Neos Therapeutics, Inc. Announces the Appointment of Vipin K. Garg, Ph.D. as Chief Executive Officer and Board Director

  Neos Therapeutics, Inc. Announces the Appointment of Vipin K. Garg, Ph.D. as
  Chief Executive Officer and Board Director

Business Wire

GRAND PRAIRIE, Texas -- October 22, 2013

Neos Therapeutics, Inc. (Neos), a highly differentiated oral drug delivery
company with an exciting portfolio of proprietary technologies and a pipeline
of innovative controlled release (CR) products, announced today the
appointment of Vipin K. Garg, Ph.D. to the role of Chief Executive Officer,
effective immediately. Dr. Garg succeeds Neos Interim Chief Executive Officer,
Alan Heller, who will continue serving as Chairman of the Neos Board of
Directors. Dr. Garg will also serve as a member of the Neos Board of
Directors.

Dr. Garg has over twenty-five years of experience within the biotechnology and
pharmaceutical industries in both technical and management positions. He has a
proven track record of building and managing both private and publicly traded
companies. Before joining Neos Therapeutics, he served as President and Chief
Executive Officer of Tranzyme Pharma (NASDAQ: TZYM), where he led the
company’s initial public offering in 2011 and its merger with Ocera
Therapeutics (NASDAQ: OCRX), Inc. in July, 2013.

Neos Therapeutics’ Chairman, Al Heller, stated, “I am excited to welcome Vipin
to the Neos team. He brings to us a wealth of strategic, scientific and
industry experience. Vipin will work closely with the organization to obtain
FDA approval of our existing pipeline, and expand the use of our proprietary
controlled release technologies to create additional CR orally disintegrating
tablets and CR liquids to bring to market.”

Prior to joining Tranzyme, Dr. Garg served as Chief Operating Officer of Apex
Bioscience, Inc. (now Curacyte AG of Munich, Germany), and held senior
management positions at DNX Bio-Therapeutics, Inc. until its acquisition by
Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known
as Sepracor Inc., now a subsidiary of Dainippon Sumitomo Pharma), and
Bio-Response Inc. (acquired by Baxter Healthcare Corporation).

Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of
Adelaide, Australia, and his M.S. from New Delhi, India in 1978. He was a
member of the U.S. Presidential Mission to India led by President Bill Clinton
in March, 2000. He is a past board member of the North Carolina Biotechnology
Center and currently serves on the Executive Committee of CED (formerly the
Council for Entrepreneurial Development). He was the recipient of the Ernst &
Young Entrepreneur of the Year 2009 Award, Carolinas Region.

"I am delighted to join Neos Therapeutics," said Dr. Garg. "Neos has developed
proprietary controlled release technologies. These technologies are being
utilized to develop a pipeline of novel ADHD products which will advance
significantly in the next 12-18 months. Building on the approval of a generic
of Tussionex®, an extended release cough cold product developed utilizing the
Neos technology and manufactured exclusively by Neos, the company is well
positioned for growth. I look forward to working with the Neos team to expand
the pipeline to additional opportunities including prescription,
over-the-counter and veterinary products in a wide range of therapeutic areas.
“

About Neos Therapeutics

Neos Therapeutics Inc. is a specialty pharmaceutical company focused on the
development, manufacture and sale of FDA approved drug products that utilize
the company’s proprietary delivery technologies. The Neos drug products are
being developed using the Dynamic Time Release Suspension® (DTRS®) and Rapidly
Disintegrating Ionic Masking™ (RDIM™) technologies that deliver controlled
release (CR) small molecule active pharmaceutical ingredients (APIs) in either
liquid or orally disintegrating tablet (ODT) dosage forms. By utilizing APIs
that are FDA-approved and known to be safe and effective, Neos can reduce
development and regulatory risk and efficiently advance targeted proprietary
Rx products through the FDA’s New Drug Application (NDA) approval process. For
more information, visit www.neostx.com.

Dynamic Time Release Suspension® ^ and DTRS® are registered trademarks of Neos
Therapeutics, LP, an affiliate of Neos Therapeutics, Inc., and Rapidly
Disintegrating Ionic Masking™ and RDIM™ are trademarks of Neos Therapeutics,
Inc.

This press release contains certain ''forward-looking statements'' that
include projections and may also include words such as ''may'', ''will'',
''expects'', ''believes'', ''anticipates'', ''plans'', ''estimates'',
''seeks'', ''could'', ''intends'', and other similar expressions. These
forward-looking statements involve risks, uncertainties, assumptions and other
factors that are difficult to predict and that could cause actual results to
vary materially from what is expressed in or indicated by the forward-looking
statements.

Contact:

Neos Therapeutics, Inc.
Ellen Hoffing, 847-597-1980
Co-President & COO
ehoffing@neostx.com
 
Press spacebar to pause and continue. Press esc to stop.